Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Page 1
Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE.
Ageno W, Farjat A, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, Angchaisuksiri P, Dalsgaard Nielsen J, Kayani G, Schellong S, Bounameaux H, Mantovani LG, Prandoni P, Kakkar AK. Ageno W, et al. Among authors: turpie agg. Res Pract Thromb Haemost. 2021 Feb 20;5(2):326-341. doi: 10.1002/rth2.12482. eCollection 2021 Feb. Res Pract Thromb Haemost. 2021. PMID: 33733032 Free PMC article.
INTRODUCTION: Venous thromboembolism (VTE) has a long-term risk of recurrence, dependent on the presence or absence of provoking risk factors at the time of the event. ...
INTRODUCTION: Venous thromboembolism (VTE) has a long-term risk of recurrence, dependent on the presence or absence of provoking risk …
Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.
Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK; GARFIELD-AF Investigators. Fox KAA, et al. Among authors: turpie agg. JAMA Netw Open. 2020 Feb 5;3(2):e200107. doi: 10.1001/jamanetworkopen.2020.0107. JAMA Netw Open. 2020. PMID: 32101311 Free PMC article.
Patients treated with OAC plus AP also had higher rates of all clinical outcomes than those treated with OAC alone over the short term (3 months). CONCLUSIONS AND RELEVANCE: This study challenges the practice of coprescribing OAC plus AP unless there is a clear indication …
Patients treated with OAC plus AP also had higher rates of all clinical outcomes than those treated with OAC alone over the short term …
New artificial intelligence prediction model using serial prothrombin time international normalized ratio measurements in atrial fibrillation patients on vitamin K antagonists: GARFIELD-AF.
Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK. Goto S, et al. Among authors: turpie agg. Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):301-309. doi: 10.1093/ehjcvp/pvz076. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 31821482 Free PMC article.
The AI model was constructed with multilayer neural network including long short-term memory and one-dimensional convolution layers. The neural network was trained using PT-INR measurements within days 0-30 after starting treatment and clinical outcomes over days 31-365 in …
The AI model was constructed with multilayer neural network including long short-term memory and one-dimensional convolution layers. …
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.
Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Verheugt FWA, et al. Among authors: turpie agg. Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12. Am J Med. 2019. PMID: 31306621
BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are in need of additional antithrombotic therapy. There are few data on the long-term clinical outcome of atrial fibrillation patients w …
BACKGROUND: Many patients with atrial fibrillation have concomitant coronary artery disease with or without acute coronary syndromes and are …
Global Anticoagulant Registry in the Field - Venous Thromboembolism (GARFIELD-VTE). Rationale and design.
Weitz JI, Haas S, Ageno W, Angchaisuksiri P, Bounameaux H, Nielsen JD, Goldhaber SZ, Goto S, Kayani G, Mantovani L, Prandoni P, Schellong S, Turpie AG, Kakkar AK. Weitz JI, et al. Among authors: turpie ag. Thromb Haemost. 2016 Nov 30;116(6):1172-1179. doi: 10.1160/TH16-04-0335. Epub 2016 Sep 22. Thromb Haemost. 2016. PMID: 27656711
VTE management aims to reduce mortality, the risks of recurrence, and long-term complications. VTE treatment is evolving with the introduction of non-vitamin K antagonist anticoagulants (NOACs). ...
VTE management aims to reduce mortality, the risks of recurrence, and long-term complications. VTE treatment is evolving with the int …
Spotlight on real-world evidence for the treatment of DVT: XALIA.
Ageno W, Turpie AG. Ageno W, et al. Among authors: turpie ag. Thromb Haemost. 2016 Sep 28;116(Suppl. 2):S41-S49. doi: 10.1160/TH16-06-0488. Epub 2016 Sep 14. Thromb Haemost. 2016. PMID: 27623684
Real-world evidence now helps to further support data from RCTs, and also bridges the gap for physicians regarding any areas of clinical uncertainty that may not be addressed by RCTs. XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in venous thromb …
Real-world evidence now helps to further support data from RCTs, and also bridges the gap for physicians regarding any areas of clinical unc …
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
Ageno W, Mantovani LG, Haas S, Kreutz R, Monje D, Schneider J, van Eickels M, Gebel M, Zell E, Turpie AG. Ageno W, et al. Among authors: turpie ag. Lancet Haematol. 2016 Jan;3(1):e12-21. doi: 10.1016/S2352-3026(15)00257-4. Epub 2015 Dec 8. Lancet Haematol. 2016. PMID: 26765643
However, data about rivaroxaban use in routine clinical practice are needed. METHODS: XA inhibition with rivaroxaban for Long-term and Initial Anticoagulation in venous thromboembolism (XALIA) was a multicentre, international, prospective, non-interventional study of patie …
However, data about rivaroxaban use in routine clinical practice are needed. METHODS: XA inhibition with rivaroxaban for Long-term an …
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis.
Ageno W, Mantovani LG, Haas S, Kreutz R, Haupt V, Schneider J, Turpie AG. Ageno W, et al. Among authors: turpie ag. Thromb J. 2014 Jul 14;12:16. doi: 10.1186/1477-9560-12-16. eCollection 2014. Thromb J. 2014. PMID: 25093014 Free PMC article.
In EINSTEIN DVT, rivaroxaban was non-inferior to enoxaparin/vitamin K antagonists for the reduction of recurrent VTE, with a similar safety profile and a net clinical benefit. EINSTEIN EXT investigated patients receiving long-term treatment in whom there was no clear decis …
In EINSTEIN DVT, rivaroxaban was non-inferior to enoxaparin/vitamin K antagonists for the reduction of recurrent VTE, with a similar safety …
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
Turpie AG. Turpie AG. Expert Rev Cardiovasc Ther. 2014 Aug;12(8):963-76. doi: 10.1586/14779072.2014.938055. Epub 2014 Jul 12. Expert Rev Cardiovasc Ther. 2014. PMID: 25017622 Review.
Patients with acute coronary syndrome (ACS) are typically managed with long-term dual antiplatelet therapy of acetylsalicylic acid plus a P2Y12 platelet receptor antagonist; however, although effective, the risk of another vascular event within 12 months remains at approxi …
Patients with acute coronary syndrome (ACS) are typically managed with long-term dual antiplatelet therapy of acetylsalicylic acid pl …
39 results